Xenon Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate UpdateWednesday, May 17, 2017
Burnaby, BC, May 17, 2017--(T-Net)--Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company today, reported its financial results for the quarter ended March 31, 2017, and provided a corporate update for 2017.
Dr. Simon Pimstone, Xenon's President and Chief Executive Officer, said, “We continue to leverage our expertise in human genetics and ion channel targets to advance our neurology-focused product candidates and identify potential new therapeutic assets. In addition to our two partnered programs in pain and our proprietary XEN901 epilepsy program, we recently expanded our ion channel, neurology-focused pipeline to include XEN1101, a Kv7 potassium channel opener for the treatment of epilepsy.”
Dr. Pimstone added, “We are positioned to see a number of key events in the coming months including topline data expected mid-year from the Phase 2b clinical trial of TV-45070 in post-herpetic neuralgia being conducted by our collaborator, Teva. We anticipate Genentech will advance GDC-0310 into a Phase 2 clinical trial this year. Within our proprietary programs, we anticipate that XEN1101 will be in a Phase 1 clinical trial in the fourth quarter of 2017. In addition, we look forward to filing an IND, or IND equivalent application, for XEN901 in the fourth quarter of this year.”
Achievements and Anticipated Milestones
First Quarter 2017 Financial Results
Cash and cash equivalents and marketable securities as of March 31, 2017 were $58.0 million, compared to $64.1 million as of December 31, 2016. There were 17,996,680 common shares outstanding as of March 31, 2017.
For the quarter ended March 31, 2017, Xenon reported total revenue of $0.02 million, compared to $0.6 million for the same period in 2016. The decrease of $0.6 million was primarily attributable to revenue recognized related to the upfront payment from the March 2014 genetics collaborative agreement with Genentech which was fully recognized by March 2016. The remaining decrease was due to less full time equivalent funding from collaborative partners as resources were shifted from supporting collaborations to Xenon's proprietary programs.
Research and development expenses for the quarter ended March 31, 2017 were $5.9 million, compared to $4.4 million for the same period in 2016. The increase of $1.5 million was primarily attributable to increased spending on XEN801 and XEN901 product candidates as well as internal preclinical and discovery programs, partially offset by a decrease in collaboration expenses.
General and administrative expenses for the quarter ended March 31, 2017 were $2.1 million, compared to $1.9 million for the same period in 2016. The increase of $0.2 million was primarily attributable to increased costs for business development and salaries and benefits, partially offset by the fair value adjustment on liability classified stock options.
Other income for the quarter ended March 31, 2017 was $0.5 million, compared to $2.4 million for the same period in 2016. The decrease of $1.9 million was primarily driven by a decrease in unrealized foreign exchange gains arising from the translation of Canadian denominated balances to U.S. dollars.
Net loss for the quarter ended March 31, 2017 was $7.5 million, compared to $3.3 million for the same period in 2016. The change was primarily attributable to lower revenue, higher research and development and general and administrative expenses and lower unrealized foreign exchange gains.
About Xenon Pharmaceuticals Inc.
Xenon is a clinical stage biopharmaceutical company focused on developing innovative therapeutics to improve the lives of patients with neurological disorders. Building upon our extensive knowledge of human genetics and diseases caused by mutations in ion channels, known as channelopathies, we are advancing - both independently and with our pharmaceutical collaborators - a novel product pipeline of ion channel modulators to address therapeutic areas of high unmet medical need, such as pain and epilepsy. For more information, please visitwww.xenon-pharma.com.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995 and Canadian securities laws.
These forward-looking statements are not based on historical fact, and include statements regarding our ability to achieve milestones in both our proprietary and partnered development programs, the anticipated read out of topline results from the Phase 2b clinical trial of TV-45070, the anticipated timing of IND or IND equivalent submissions with regulatory agencies, the initiation of future clinical trials, the timing of and results from our and our collaborators' ongoing clinical trials and pre-clinical development activities, the plans of our collaboration partners and their interactions with regulatory agencies, the potential efficacy, future development plans and commercial potential of our and our collaborators' product candidates and the progress and potential of ongoing development programs.
These forward-looking statements are based on current assumptions that involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements.
These risks and uncertainties, many of which are beyond our control, include, but are not limited to: clinical trials may not demonstrate safety and efficacy of any of our or our collaborators' product candidates; our discovery platform or ongoing collaborations may not yield additional product candidates; any of our or our collaborators' product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; we may not achieve additional milestones pursuant to our collaboration agreements; the impact of competition; the impact of expanded product development and clinical activities on operating expenses; adverse conditions in the general domestic and global economic markets; as well as the other risks identified in our filings with the Securities and Exchange Commission and the securities commissions in British Columbia, Alberta and Ontario.
These forward-looking statements speak only as of the date hereof and we assume no obligation to update these forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements.
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
|XENON PHARMACEUTICALS INC.|
|Condensed Consolidated Balance Sheets|
|(Expressed in thousands of U.S. dollars)|
|March 31,||December 31,|
|Cash and cash equivalents and marketable securities||$||58,027||$||64,146|
|Other current assets||1,114||1,529|
|Accounts payable and accrued expenses||3,591||3,586|
|Total liabilities and shareholders' equity||$||60,786||$||67,487|
XENON PHARMACEUTICALS INC.
|Condensed Consolidated Statements of Operations|
|(Expressed in thousands of U.S. dollars except share and per share amounts)|
|Three Months Ended March 31,|
|Research and development||5,903||4,364|
|General and administrative||2,100||1,895|
|Total operating expenses||8,003||6,259|
|Loss from operations||(7,987||)||(5,658||)|
|Net loss per common share:|
|Weighted-average common shares outstanding:|
Burnaby, BC (Biotech/Life Sciences)
Other Recent Company News
Xenon Pharmaceuticals Inc.
Copyright © T-NET. All Rights Reserved. | https://www.bctechnology.com